| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000003319 |
| Receipt No. | R000003941 |
| Scientific Title | A phase III study of laparoscopy assisted versus open distal gastrectomy with nodal dissection for clinical stage I gastric cancer (JCOG0912, cSt-I GC LADG P3) |
| Date of disclosure of the study information | 2010/03/12 |
| Last modified on | 2022/08/30 (Ver. 9) |
| Basic information | ||
| Public title | A phase III study of laparoscopy assisted versus open distal gastrectomy with nodal dissection for
clinical stage I gastric cancer (JCOG0912, cSt-I GC LADG P3) |
|
| Acronym | A phase III study of laparoscopy assisted versus open distal gastrectomy with nodal dissection for
clinical stage I gastric cancer (JCOG0912, cSt-I GC LADG P3) |
|
| Scientific Title | A phase III study of laparoscopy assisted versus open distal gastrectomy with nodal dissection for
clinical stage I gastric cancer (JCOG0912, cSt-I GC LADG P3) |
|
| Scientific Title:Acronym | A phase III study of laparoscopy assisted versus open distal gastrectomy with nodal dissection for
clinical stage I gastric cancer (JCOG0912, cSt-I GC LADG P3) |
|
| Region |
|
|
| Condition | ||
| Condition | gastric cancer | |
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To demonstrate the non-inferiority of relapse-free survival of laparoscopy assisted distal gastrectomy (LADG) with nodal dissection compared with open gastrectomy for clinical T1N0, T1N1 or T2(MP)N0 gastric cancer. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | |
| Developmental phase | Phase III |
| Assessment | |
| Primary outcomes | Relapse-free survival |
| Key secondary outcomes | Overall survival , proportion of LADG completion, proportion of conversion to open surgery, adverse events, short-term clinical outcomes, postoperative QOL |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -no one is blinded |
| Control | Active |
| Stratification | NO |
| Dynamic allocation | YES |
| Institution consideration | Institution is considered as adjustment factor in dynamic allocation. |
| Blocking | NO |
| Concealment | Central registration |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | A: Open distal gastrectomy with nodal dissection | |
| Interventions/Control_2 | B: Laparoscopy assisted distal gastrectomy (LADG) with nodal dissection | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) Histologically proven gastric adenocarcinoma.
2) cStage IA(T1N0) or IB(T1N1, T2[MP]N0). 3) In case without preceding endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD), either 'cN1' or 'cN0 and no indication of EMR' is eligible. 4) In case with preceding EMR or ESD, the following conditions are fulfilled: i) pathological findings require additional gastrectomy, ii) within 56 days from EMR, iii) no perforation by EMR, iv) resection margin of EMR did not reach to the upper third of the stomach. 5) Tumor located in the middle or lower third of the stomach, and curative resection is expected to be achivable by distal gastrectomy. 6) No invasion to duodenum. 7) Aged 20 to 80 years. 8) PS (ECOG) of 0 or 1. 9) Body mass index less than 30. 10) No history of upper abdominal surgery and no history of intestinal resection. 11) No prior treatment of chemotherapy or radiation therapy against any other malignancies. 12) Sufficient organ functions. 13) Written informed consent. |
|||
| Key exclusion criteria | 1) Synchronous or metachronous (within 5 years) malignancies other than carcinoma in situ.
2) Infectious disease with systemic therapy indicated. 3) Body temperature of 38 or more degrees Celsius. 4) Women during pregnancy or breast-feeding. 5) Severe mental disease. 6) Continuous systemic steroid therapy. 7) Unstable angina pectoris, or history of myocardial infarction within six months. 8) Uncontrollable hypertension. 9) Uncontrollable diabetes millutus or administration of insulin. 10) Severe respiratory disease requiring continuous oxygen therapy. |
|||
| Target sample size | 920 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | National Cancer Center Hospital | ||||||
| Division name | Gastric Surgery Division | ||||||
| Zip code | |||||||
| Address | 5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, JAPAN | ||||||
| TEL | 03-3542-2511 | ||||||
| JCOG_sir@ml.jcog.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | JCOG0912 Coordinating Office | ||||||
| Division name | Gastric Surgery Division, National Cancer Center Hospital | ||||||
| Zip code | |||||||
| Address | 5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, JAPAN | ||||||
| TEL | 03-3542-2511 | ||||||
| Homepage URL | http://www.jcog.jp/ | ||||||
| JCOG_sir@ml.jcog.jp | |||||||
| Sponsor | |
| Institute | Japan Clinical Oncology Group(JCOG) |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Ministry of Health, Labour and Welfare |
| Organization | |
| Division | |
| Category of Funding Organization | |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | |
| Address | |
| Tel | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 函館厚生院函館五稜郭病院(北海道)
恵佑会札幌病院(北海道) 岩手医科大学(岩手県) 国立病院機構仙台医療センター(宮城県) 山形県立中央病院(山形県) 栃木県立がんセンター(栃木県) 国立がん研究センター東病院(千葉県) 国立がん研究センター中央病院(東京都) がん・感染症センター都立駒込病院(東京都) 東京医科歯科大学(東京都) がん研究会有明病院(東京都) 虎の門病院(東京都) 神奈川県立病院機構(神奈川県) 北里大学医学部(神奈川県) 横浜市立大学附属市民総合医療センター(神奈川県) 富山県立中央病院(富山県) 石川県立中央病院(石川県) 岐阜大学医学部(岐阜県) 静岡県立総合病院(静岡県) 静岡県立静岡がんセンター(静岡県) 愛知県がんセンター中央病院(愛知県) 名古屋大学医学部(愛知県) 国立病院機構京都医療センター(京都府) 大阪大学医学部(大阪府) 近畿大学医学部(大阪府) 大阪府立病院機構(大阪府) 大阪医科大学(大阪府) 関西医科大学附属枚方病院(大阪府) 大阪労災病院(大阪府) 神戸大学医学部(兵庫県) 関西労災病院(兵庫県) 兵庫医科大学(兵庫県) 兵庫県立がんセンター(兵庫県) 天理よろづ相談所病院(奈良県) 和歌山県立医科大学(和歌山県) 島根大学医学部(島根県) 岡山大学病院(岡山県) 広島市立広島市民病院(広島県) 福山市民病院(広島県) 国立病院機構四国がんセンター(愛媛県) 大分大学医学部附属病院(大分県) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003941 |